A detailed history of Black Rock Inc. transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,756,219 shares of CABA stock, worth $18.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,756,219
Previous 4,057,113 17.23%
Holding current value
$18.8 Million
Previous $69.2 Million 48.6%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$7.22 - $18.82 $5.05 Million - $13.2 Million
699,106 Added 17.23%
4,756,219 $35.6 Million
Q1 2024

May 10, 2024

SELL
$16.79 - $25.38 $5.91 Million - $8.93 Million
-351,892 Reduced 7.98%
4,057,113 $69.2 Million
Q4 2023

Feb 13, 2024

BUY
$12.21 - $23.36 $24 Million - $45.9 Million
1,966,808 Added 80.53%
4,409,005 $100 Million
Q3 2023

Nov 13, 2023

BUY
$11.84 - $18.65 $8.67 Million - $13.7 Million
732,479 Added 42.84%
2,442,197 $37.2 Million
Q2 2023

Aug 11, 2023

BUY
$7.65 - $13.95 $11.3 Million - $20.6 Million
1,477,768 Added 637.11%
1,709,718 $22.1 Million
Q1 2023

May 12, 2023

SELL
$7.08 - $12.62 $214,913 - $383,080
-30,355 Reduced 11.57%
231,950 $1.92 Million
Q4 2022

Feb 13, 2023

SELL
$0.64 - $9.3 $112,434 - $1.63 Million
-175,679 Reduced 40.11%
262,305 $2.43 Million
Q3 2022

Nov 14, 2022

SELL
$0.63 - $2.05 $38,308 - $124,654
-60,807 Reduced 12.19%
437,984 $285,000
Q2 2022

Aug 12, 2022

SELL
$0.99 - $2.11 $11,678 - $24,889
-11,796 Reduced 2.31%
498,791 $529,000
Q1 2022

May 12, 2022

BUY
$1.68 - $3.92 $10,746 - $25,076
6,397 Added 1.27%
510,587 $1.04 Million
Q4 2021

Feb 10, 2022

BUY
$3.36 - $14.64 $583,662 - $2.54 Million
173,709 Added 52.56%
504,190 $1.91 Million
Q3 2021

Nov 09, 2021

BUY
$7.0 - $12.5 $93,051 - $166,162
13,293 Added 4.19%
330,481 $4.02 Million
Q2 2021

Aug 11, 2021

BUY
$7.2 - $11.73 $2.28 Million - $3.72 Million
317,188 New
317,188 $2.73 Million

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $115M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.